Insider Selling: Maplight Therapeutics (NASDAQ:MPLT) Director Sells 7,039 Shares of Stock

Maplight Therapeutics, Inc. (NASDAQ:MPLT) Director Robert Malenka sold 7,039 shares of the company’s stock in a transaction on Monday, February 2nd. The shares were sold at an average price of $18.02, for a total transaction of $126,842.78. Following the sale, the director owned 358,234 shares of the company’s stock, valued at $6,455,376.68. This represents a 1.93% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Maplight Therapeutics Price Performance

NASDAQ:MPLT traded down $0.31 during mid-day trading on Wednesday, reaching $16.80. 193,720 shares of the company’s stock traded hands, compared to its average volume of 182,355. The firm’s 50 day moving average is $17.88. Maplight Therapeutics, Inc. has a 12-month low of $12.24 and a 12-month high of $21.55.

Maplight Therapeutics (NASDAQ:MPLT) last issued its quarterly earnings data on Thursday, December 4th. The company reported ($37.18) EPS for the quarter, missing the consensus estimate of ($1.86) by ($35.32).

Hedge Funds Weigh In On Maplight Therapeutics

A hedge fund recently bought a new stake in Maplight Therapeutics stock. Strs Ohio acquired a new stake in shares of Maplight Therapeutics, Inc. (NASDAQ:MPLT) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 3,000 shares of the company’s stock, valued at approximately $53,000.

Analyst Ratings Changes

Several equities analysts recently issued reports on the company. Leerink Partners assumed coverage on Maplight Therapeutics in a research report on Friday, November 21st. They issued an “outperform” rating and a $30.00 price objective on the stock. Morgan Stanley initiated coverage on Maplight Therapeutics in a research note on Friday, November 21st. They issued an “overweight” rating and a $34.00 price target for the company. Zacks Research raised Maplight Therapeutics to a “hold” rating in a research report on Monday, November 24th. Wall Street Zen upgraded Maplight Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, December 20th. Finally, Weiss Ratings initiated coverage on shares of Maplight Therapeutics in a research note on Thursday, January 22nd. They set a “sell (e)” rating on the stock. One analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Maplight Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $31.00.

Maplight Therapeutics Company Profile

We are a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system, or CNS, disorders. We were founded by globally recognized leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients. Our discovery platform holds the potential to fill this void by identifying neural circuits causally linked to disease and targeting those circuits for therapeutic modulation.